logo-loader

Midatech Pharma hails positive results from first in man study

Last updated: 11:42 19 Jul 2019 BST, First published: 07:48 19 Jul 2019 BST

1563519208_sterile-room
The trial now enters what's called the follow-up phase

Midatech Pharma PLC (LON: MTPH.L, NASDAQ:MTP) has announced positive results from a phase I clinical trial of a drug being developed to treat type-1 diabetes.

Researchers were assessing the safety of MTX102, which is being designed as a vaccine. Five patients received the drug and other than some reactions around the injection site “no serious adverse events were reported”.

“The study now enters a follow up stage, at the end of which we will review the data and programme, together with the EU consortium partners,” said Colin Dayan, the lead investigator.

The early-stage assessment was part of an EU project involving a number companies and academic bodies.

Gold nanoparticles 

They are evaluating a vaccine approach for the treatment of type-1 diabetes using Midatech’s gold nanoparticle technology.

The company’s MidaCore technology uses ultra-small gold nanoparticle drug conjugates. And, at just two nanometres, they are among the smallest particles in biomedical use.

They are composed of a core of gold atoms decorated with a permutation of an already-available drug treatment and targeting molecules.

The small size and arrangement around the gold core in theory allows the technology to target immune sites and tumours.

Midatech chief executive Craig Cook said the data generated to date from the first-in-human study helps validate the technology as a “potentially innovative treatment platform for medical applications".

---The shares rose 7% to 5.4p---

HANetf founder and co-CEO discusses shift to active management in ETF market

HANetf founder and co-CEO Hector McNeil tells Proactive's Stephen Gunnion about shifting trends in the exchange-traded fund (ETF) market in the United States, indicating a big move towards active management within ETFs. Despite the European market lagging behind the US by three to five years,...

14 hours, 38 minutes ago